StockData
Senti Biosciences Holdings, Inc. logo

Senti Biosciences Holdings, Inc. (SNTI) company profile

SNTINasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 4/30
$0.10−0.04 (-28.68%)

Close on Nov 17, 2026Market cap $3.02MP/E –Yield –

About Senti Biosciences

Biological Products, (No Diagnostic Substances), SIC 2836

Senti Biosciences is a clinical-stage biotechnology company that develops cell and gene therapies using synthetic biology and proprietary gene circuit technologies. The company programs cells with biological logic to target and destroy cancer cells while sparing healthy tissue. Its lead product candidate is SENTI-202, an off-the-shelf chimeric antigen receptor natural killer cell therapy designed to treat relapsed or refractory hematological malignancies, including acute myeloid leukemia. In addition to internal oncology initiatives, Senti Biosciences maintains preclinical programs in solid tumors and partners with BlueRock Therapeutics to develop cell therapies for regenerative medicines.

The company conducts clinical trials in the United States and Australia. Senti Biosciences has its contract clinical manufacturing performed in Alameda, California, following the sale of manufacturing assets and sublease of its facility to GeneFab. The company holds worldwide licensing agreements with the National Cancer Institute for chimeric antigen receptor technologies.

Summary of the business section of Senti Biosciences's latest annual report, written by StockData.

Company profile

Company

Legal name
Senti Biosciences Holdings, Inc.
Headquarters
South San Francisco, CA
Address
2 Corporate Drive, First Floor 94080
Phone
(650) 239-2030
Industry
Biological Products, (No Diagnostic Substances)
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
KPMG LLP, San Francisco, CA,

Stock & identifiers

Ticker
SNTI
Former tickers
DYNS until Jun 9, 2022
Exchange
Nasdaq
IPO date
May 26, 2021
Shares outstanding
31M, Jul 31, 2026
Public float
$53.20M, Jun 30, 2025
Filer category
<br>Emerging growth company
Stock splits
1-for-10 reverse, Jul 18, 2024; 1-for-10 reverse, Aug 15, 2022
SEC CIK
1854270
CUSIP
816944102
ISIN
US8169441024
FIGI
BBG021Y8RQQ5
Share class FIGI
BBG021Y8RQS3
EIN
86-2437900

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Timothy K. LuCEO, Director587,949
Kanya RajangamPres. & Chief Med. & Dev. Off.87,890
John Harry Cross IIIChief Financial Officer–
Bryan Daniel BaumDirector–
Donald F. TangDirector10,368
Edward T. MathersDirector–
James J. CollinsDirector176,130
Fran SchulzDirector–
Brenda CooperstoneDirector–
Feng HsiungDirector–

Executive compensation, fiscal 2024

Summary compensation table from the latest proxy statement

ExecutiveSalaryStock awardsOption awardsIncentive payOtherTotalvs. prior year
Timothy Lu
Chief Executive Officer
$618.76K$140.76K$159.14K$442.41K$12.03K$930.69K-45%
Kanya Rajangam
President, Head of Research and Development and Chief Medical Officer
$526.79K$46.46K$52.70K$265.50K$1.76K$858.77K+37%
Yvonne Li
Former Chief Financial Officer
––––$547.54K$547.54K–

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

Corporate history

Events identified from SEC filings

DateEventDetails
Oct 26, 2026Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Sep 24, 2026Merger voteDefinitive merger proxy statement
Sep 2, 2026Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
May 8, 2026Name changeName changed from Senti Biosciences, Inc. to Senti Biosciences Holdings, Inc.
May 8, 2026DeregistrationTermination of SEC registration (Form 15)
Oct 25, 2024Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Feb 6, 2024Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Aug 11, 2023Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Aug 10, 2023Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Jun 15, 2022Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Jun 15, 2022Auditor changeChange in certifying accountant (8-K Item 4.01)
Jun 13, 2022Name changeName changed from Dynamics Special Purpose Corp. to Senti Biosciences, Inc.\
May 13, 2022Merger voteDefinitive merger proxy statement
Feb 14, 2022MergerRegistration of securities for a merger or exchange offer (S-4)
May 25, 2021ListingRegistration of securities on an exchange (Form 8-A)

See a number that looks wrong?